Literature DB >> 25337766

Novel mutations in a patient with ALK-rearranged lung cancer.

Smith Giri1, Jashmin K Patel, Daruka Mahadevan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25337766     DOI： 10.1056/NEJMc1410799

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

Review 1.  Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.

Authors:  Kathryn C Arbour; Gregory J Riely
Journal:  Hematol Oncol Clin North Am       Date:  2017-02       Impact factor: 3.722

2.  TP53 Mutations as a Driver of Metastasis Signaling in Advanced Cancer Patients.

Authors:  Ritu Pandey; Nathan Johnson; Laurence Cooke; Benny Johnson; Yuliang Chen; Manjari Pandey; Jason Chandler; Daruka Mahadevan
Journal:  Cancers (Basel)       Date:  2021-02-03       Impact factor: 6.639

Review 3.  Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer.

Authors:  Hideko Isozaki; Nagio Takigawa; Katsuyuki Kiura
Journal:  Cancers (Basel)       Date:  2015-04-30       Impact factor: 6.639

Review 4.  Targeted therapies and immunotherapy in non-small-cell lung cancer.

Authors:  D Cortinovis; M Abbate; P Bidoli; S Capici; S Canova
Journal:  Ecancermedicalscience       Date:  2016-06-23

5.  BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.

Authors:  Juan Li; Qifeng Wang; Jun Ge; Yuke Tian; Wenxiu Yao
Journal:  Oncologist       Date:  2021-11-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.